| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Acetylshengmanol Arabinoside modulates multiple signaling pathways involved in inflammation and tumor growth. Its biological activities include anti-inflammatory, anti-tumor, and neuroprotective effects. The compound has been found to have potential roles in drug development. As a natural product derived from Cimicifuga, it likely targets pathways involved in inflammatory and cancer signaling. Further studies are needed to fully characterize its molecular targets.
|
|---|---|
| ln Vitro |
In vitro, Acetylshengmanol Arabinoside has demonstrated anti-inflammatory, anti-tumor, and neuroprotective activities. The compound has been studied for its effects on various cellular targets. It shows potential in drug development for anti-inflammatory and anti-cancer applications. Acetylshengmanol Arabinoside is an extract derived from Cimicifugae rhizoma. Its bioactivity has been characterized in various cell-based assays. Further in vitro studies are ongoing to fully characterize its pharmacological effects.
|
| ln Vivo |
In vivo, Acetylshengmanol Arabinoside has been studied for its anti-inflammatory, anti-tumor, and neuroprotective effects. The compound has potential roles in drug development. Its anti-inflammatory and anti-cancer activities have been evaluated in animal models. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is derived from Cimicifugae rhizoma, a plant used in traditional medicine.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Acetylshengmanol Arabinoside involve measuring its anti-inflammatory, anti-tumor, and neuroprotective activities. Anti-inflammatory activity is assessed by measuring cytokine production or NF-κB activation. Anti-tumor activity is evaluated by assessing cell proliferation and apoptosis. Neuroprotective effects are measured by assessing neuronal cell survival and oxidative stress markers. Assays are performed in appropriate buffer systems with positive controls. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Acetylshengmanol Arabinoside are conducted in various cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Inflammatory markers are measured by ELISA or Western blot. Neuroprotective effects are assessed in neuronal cell models. Experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal studies for Acetylshengmanol Arabinoside are conducted in rodent models of inflammation, cancer, and neurological disorders. Animals are treated with the compound via oral administration or injection. Disease progression is monitored by appropriate endpoints. For anti-inflammatory studies, animal models of inflammation are used. For anti-tumor studies, tumor-bearing mice are used. For neuroprotection, models of neurodegeneration are employed. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
Acetylshengmanol Arabinoside (MW 662.85 g/mol, C37H58O10) is a natural glycoside with moderate molecular weight. The compound is an extract derived from Cimicifugae rhizoma. It is soluble in DMSO (250 mg/mL). The compound is metabolized by deglycosylation to release the active aglycone. Pharmacokinetic parameters such as Cmax, Tmax, and half-life would be determined in species-specific studies. The compound shows stability under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Acetylshengmanol Arabinoside is generally well-tolerated in preclinical studies. The compound is a natural product derived from Cimicifugae rhizoma, a plant used in traditional medicine. Its anti-inflammatory, anti-tumor, and neuroprotective effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
It has been reported that Actaea cimicifuga and Actaea racemosa contain 23-O-acetylcidocanol-3-O-α-L-arabinoside, and relevant data are available. See also: Black cohosh (partial).
Acetylshengmanol Arabinoside is an extract derived from Cimicifugae rhizoma with anti-inflammatory, anti-tumor, and neuroprotective effects. The compound has potential roles in drug development, such as the development of anti-inflammatory and anti-cancer drugs. Acetylshengmanol Arabinoside is also known as Acetylcimigenol 3-O-alpha-L-arabinopyranoside. It has a molecular formula of C37H58O10 and a molecular weight of 662.85 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C37H58O10
|
|---|---|
| Molecular Weight |
662.8504
|
| Exact Mass |
662.403
|
| CAS # |
402513-88-6
|
| PubChem CID |
10865257
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
748.5±60.0 °C at 760 mmHg
|
| Flash Point |
225.6±26.4 °C
|
| Vapour Pressure |
0.0±5.7 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
4.14
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
47
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@H](C[C@H]([C@H]1C(O1)(C)C)OC(=O)C)[C@H]2C(=O)[C@@H]([C@@]3([C@@]2(CC[C@]45[C@H]3CC[C@@H]6[C@]4(C5)CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O)O)O)C)C)O
|
| InChi Key |
IHEJMZHKJYHVFF-NETQQFODSA-N
|
| InChi Code |
InChI=1S/C37H58O10/c1-18(15-21(45-19(2)38)30-33(5,6)47-30)25-27(41)29(43)35(8)23-10-9-22-32(3,4)24(46-31-28(42)26(40)20(39)16-44-31)11-12-36(22)17-37(23,36)14-13-34(25,35)7/h18,20-26,28-31,39-40,42-43H,9-17H2,1-8H3/t18-,20+,21-,22+,23+,24+,25+,26+,28-,29+,30+,31+,34-,35-,36-,37+/m1/s1
|
| Chemical Name |
[(1R,3R)-1-[(2S)-3,3-dimethyloxiran-2-yl]-3-[(1S,3R,6S,8R,11R,12S,13R,15R,16R)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxy-15-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]butyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~377.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5086 mL | 7.5432 mL | 15.0864 mL | |
| 5 mM | 0.3017 mL | 1.5086 mL | 3.0173 mL | |
| 10 mM | 0.1509 mL | 0.7543 mL | 1.5086 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
